埃克替尼和吉非替尼一线治疗晚期非小细胞肺癌患者的疗效观察

Clinical Observation of Icotinib and Gefitinib in First-line Therapy for advanced non-small cell lung cancer

目的 :探讨一线应用埃克替尼和吉非替尼治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床疗效和安全性。方法 :选择80例于2012年8月至2014年8月期间初次确诊为Ⅳ期NSCLC的患者,随机分为两组,一组患者口服吉非替尼,一组患者口服埃克替尼,8周后评价两组的近期疗效和不良反应,并随访和评价两组患者的生存情况。结果 :吉非替尼组的患者无完全缓解(complete remission,CR),近期有效率22.2%,疾病控制率55.6%。埃克替尼组18例患者均无CR,近期有效率为27.7%,疾病控制率为61.1%。两组患者近期有效率和疾病控制率均无差异。两组患者常见的不良反应为皮疹、腹泻。两组患者随访1年后和截止至2014年8月的PFS均没有统计学差异。结论 :埃克替尼一线治疗NSCLC的疗效与吉非替尼相似,患者耐受性优于吉非替尼。

Objective To evaluate the clinical efficacy and toxicity of ofIcotinib and Gefitinib in first-line therapy for ad-vanced non-small cell lung cancer(NSCLC). Methods From August 2012 to August 2014, eighty advanced NSCLC patients were selected in our study. Eighteen NSCLC patients were treated with Gefitinib,the others were treated with Icotinib. Clinical outcomes, adverse reactions and progression free survival were compared between the two groups. Results The response rate and disease control rate of Gefitinib in NSCLC were 22.2% and 55.6%. The response rate and disease control rate of in NSCLC were 27.7 % and 67.1%. There was no statistically significant difference between the two group. The common toxic effects were skin rash and diarrhea of the two groups. The progress free survival time were not significantly different between the two groups. Conclusion Icotinib and Gefitinib appear to have similar antitumor activity and safety in patients with advanced NSCLC.